The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The leaves contain several active alkaloids, primarily mitragynine and 7-hydroxymitragynine, which act as partial agonists at ...

Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...

This review addresses open questions about the role of β-adrenergic receptors in cardiac function and failure. Cardiomyocytes express all three β-adrenergic receptor subtypes—β1, β2, and, at least in ...

The β-adrenergic receptor kinase (βARK) specifically phosphorylates and thereby inactivates β-adrenergic receptors after stimulation by receptor agonists, facilitating the binding of the inhibitor ...

The combination of a β-adrenergic receptors (AR) blocker and a carbonic anhydrase (CA, EC 4.2.1.1) inhibitor in eye drops formulations is one of the most clinically used treatment for glaucoma. A ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

To address this question, we performed NMR studies on ∼35-residue-long peptides including the critical second intracellular loop (i2) of the α2A adrenergic receptor (AR) and of rhodopsin.

A new oral drug mimics exercise, burns fat, lowers blood sugar, and preserves muscle mass, potentially outperforming Ozempic ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Shane Wright, Assistant Professor at the Department of Physiology and Pharmacology, and colleagues have uncovered a new way to tailor signaling ...